PET117 — Cytochrome C Oxidase Assembly Factor

PET117 — Cytochrome C Oxidase Assembly Factor

<div class="infobox infobox-gene">
<div class="infobox-header">PET117</div>

Overview

PET117 encodes Cytochrome C Oxidase Assembly Factor PET117, a nuclear-encoded mitochondrial protein essential for the proper assembly and stability of mitochondrial complex IV (cytochrome c oxidase, COX). PET117 was originally characterized in yeast as a required factor for cytochrome c oxidase assembly, and the human ortholog serves a conserved function in mitochondrial respiration[@ostergaard2007]. Given the critical role of complex IV in the electron transport chain (ETC) and the high energy demands of neurons, PET117 dysfunction has significant implications for neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, and related mitochondrial encephalopathies[@capitani2019].

PET117 — Cytochrome C Oxidase Assembly Factor

<div class="infobox infobox-gene">
<div class="infobox-header">PET117</div>

Overview

PET117 encodes Cytochrome C Oxidase Assembly Factor PET117, a nuclear-encoded mitochondrial protein essential for the proper assembly and stability of mitochondrial complex IV (cytochrome c oxidase, COX). PET117 was originally characterized in yeast as a required factor for cytochrome c oxidase assembly, and the human ortholog serves a conserved function in mitochondrial respiration[@ostergaard2007]. Given the critical role of complex IV in the electron transport chain (ETC) and the high energy demands of neurons, PET117 dysfunction has significant implications for neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, and related mitochondrial encephalopathies[@capitani2019].

<div class="infobox-row">
<span class="infobox-label">Gene Symbol</span>
<span class="infobox-value">PET117</span>
</div>
<div class="infobox-row">
<span class="infobox-label">Full Name</span>
<span class="infobox-value">Cytochrome C Oxidase Assembly Factor PET117</span>
</div>
<div class="infobox-row">
<span class="infobox-label">Chromosomal Location</span>
<span class="infobox-value">19q13.11</span>
</div>
<div class="infobox-row">
<span class="infobox-label">NCBI Gene ID</span>
<span class="infobox-value">[55028](https://www.ncbi.nlm.nih.gov/gene/55028)</span>
</div>
<div class="infobox-row">
<span class="infobox-label">OMIM</span>
<span class="infobox-value">[614970](https://www.omim.org/entry/614970)</span>
</div>
<div class="infobox-row">
<span class="infobox-label">Ensembl ID</span>
<span class="infobox-value">[ENSG00000157103](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157103)</span>
</div>
<div class="infobox-row">
<span class="infobox-label">UniProt ID</span>
<span class="infobox-value">[Q8N5N7](https://www.uniprot.org/uniprot/Q8N5N7)</span>
</div>
<div class="infobox-row">
<span class="infobox-label">Protein Class</span>
<span class="infobox-value">Mitochondrial Assembly Factor</span>
</div>
<div class="infobox-row">
<span class="infobox-label">Associated Diseases</span>
<span class="infobox-value">Complex IV deficiency, Leigh syndrome, Parkinson's disease, Alzheimer's disease, mitochondrial encephalopathies</span>
</div>
</div>

Protein Structure and Function

Molecular Function

PET117 participates in complex IV assembly through several mechanisms[@barrientos2015][@fernandez2019]:

Assembly Factor Activity:

• PET117 functions as a specialized assembly factor for cytochrome c oxidase
• The protein localizes to the inner mitochondrial membrane
• It facilitates the incorporation of nuclear-encoded subunits into the growing complex
• PET117 interacts with other assembly factors in the COX assembly pathway

• Participates in the late stages of COX assembly
• Helps stabilize the fully assembled complex
• Ensures proper subunit stoichiometry
• Facilitates heme a and copper center incorporation

• May assist in the turnover of malformed complexes
• Prevents accumulation of toxic assembly intermediates
• Maintains mitochondrial respiratory integrity

Structure

PET117 is a mitochondrial protein with characteristic features:

• N-terminal mitochondrial targeting sequence: A cleavable presequence that directs import into mitochondria
• Transmembrane domain: Anchors the protein to the inner mitochondrial membrane
• Matrix-facing domain: Contains functional regions for assembly factor activity

Mitochondrial Complex IV (Cytochrome C Oxidase)

Structure and Function

Complex IV (cytochrome c oxidase) is the terminal enzyme of the electron transport chain[@carr2003]:

Subunit Composition:

• 13 subunits in mammals (3 mitochondrial-encoded, 10 nuclear-encoded)
• Contains two heme groups (heme a and a3) and two copper centers (CuA and CuB)
• Catalytic core formed by subunits I, II, and III

Proton Pumping:

• Pumps 4 protons per electron pair across inner membrane
• Contributes to electrochemical gradient (Δψm)

Assembly Pathway

Complex IV assembly follows an ordered process:

PET117 participates specifically in the late assembly stages, distinguishing it from early assembly factors like COX14 and COX10.

Role in Normal Cellular Function

Energy Production

PET117 is essential for mitochondrial respiration[@mick2012]:

ATP Generation:

• Complex IV is rate-limiting for ETC flux
• Proper assembly ensures efficient ATP production
• Critical for high-energy cells (neurons, cardiomyocytes)

• Maintains proton motive force
• Couples electron transport to ATP synthesis
• Affects overall metabolic rate

Neuronal Function

Neurons have particular reliance on PET117 function:

• High metabolic demands of action potentials
• Synaptic vesicle cycling requires ATP
• Axonal transport is energy-dependent
• Ionic pump function depends on ATP

Disease Associations

Complex IV Deficiency

PET117 mutations can cause complex IV deficiency[@pecina2004]:

Leigh Syndrome:

• Severe childhood encephalopathy
• Neurodegeneration in brainstem regions
• Elevated lactate in blood and CSF
• Characteristic lesions on MRI

• Isolated complex IV activity loss
• Variable severity
• May cause cardiomyopathy
• Hypotonia and developmental delay

Parkinson's Disease

Complex IV has specific relevance to PD[@hernandez2019]:

Complex I Deficit:

• While primarily complex I is affected in PD, complex IV is also altered
• PET117 expression may be dysregulated
• Mitochondrial dysfunction is central to PD pathogenesis

• Substantia nigra neurons have high mitochondrial demands
• Complex IV impairment adds to stress
• Contributes to cell death

Alzheimer's Disease

PET117 connections to AD[@petit2017]:

• Complex IV activity reduced in AD brain
• Mitochondrial dysfunction is an early event
• Amyloid-beta toxicity affects complex IV
• Energy failure contributes to neurodegeneration

Aging

Age-related changes in complex IV:

• Complex IV activity declines with age
• Contributes to age-related cognitive decline
• PET117 expression may change
• Mitochondrial biogenesis impairment

Therapeutic Implications

Targeting Mitochondrial Function

Gene Therapy Potential

• Viral vector delivery of functional PET117
• CRISPR-based gene correction
• Targeting mitochondrial genome

Molecular Mechanisms in Neurodegeneration

Complex IV and Neuronal Energy Crisis

The brain's extraordinary energy demands make neurons particularly vulnerable to complex IV dysfunction. PET117, as a critical assembly factor, plays a central role in maintaining complex IV integrity. When PET117 function is compromised, the resulting complex IV deficiency creates a cascading failure of mitochondrial function that ultimately leads to neuronal death[@sz升学2021].

The energy crisis in neurodegeneration involves several interconnected mechanisms:

The sequential nature of the electron transport chain means that complex IV deficiency creates a bottleneck that causes electrons to back up through complexes I and III, generating excessive superoxide radicals. This feed-forward mechanism amplifies oxidative damage and accelerates neurodegeneration.

Oxidative Stress and Protein Aggregation

Complex IV deficiency contributes to oxidative stress, which is a central mechanism in both Alzheimer's and Parkinson's disease pathogenesis:

ROS Production:

• Electron leakage from damaged complex IV increases superoxide production
• Antioxidant defenses become overwhelmed
• Lipid peroxidation damages cellular membranes
• DNA damage accumulates
• Protein carbonylation disrupts enzyme function

• Oxidative stress promotes protein misfolding
• Amyloid-beta aggregation may be accelerated
• Alpha-synuclein oxidation increases
• Tau pathology is exacerbated

Synaptic Dysfunction

The synapse is particularly vulnerable to mitochondrial dysfunction due to its high energy requirements for vesicle cycling, receptor trafficking, and ion pump function:

Presynaptic Effects:

• Reduced ATP impairs vesicle recycling
• Synaptic vesicle pool becomes depleted
• Neurotransmitter release is compromised
• Calcium buffering is disrupted

• Ion gradient maintenance fails
• NMDA receptor dysfunction occurs
• Spine morphology is altered
• LTP induction is impaired

Neuroinflammation

Mitochondrial complex IV deficiency triggers neuroinflammatory responses through multiple pathways:

• DAMPs (damage-associated molecular patterns) are released from dysfunctional mitochondria
• Microglial activation is induced by mitochondrial debris
• Pro-inflammatory cytokines are upregulated in response to mitochondrial stress
• The innate immune system is engaged through pattern recognition receptors

PET117 in Model Systems

Yeast Models

Yeast PET117 has been extensively studied as a model for complex IV assembly. Yeast deletion mutants show:

• Severe growth defects on non-fermentable carbon sources
• Incomplete complex IV assembly
• Accumulation of assembly intermediates
• Loss of cytochrome c oxidase activity

Cell Culture Models

In vitro models have been developed to study PET117:

• Patient-derived fibroblasts: Show complex IV deficiency
• iPSC-derived neurons: Allow disease modeling
• CRISPR-edited cell lines: Enable mechanistic studies

PET117 Signaling Network

Interaction Partners

PET117 interacts with several proteins in the complex IV assembly pathway:

• SURF1: Core assembly factor
• COX10: Heme a biosynthesis
• COX14: Early assembly factor
• COX15: Heme o/a synthesis
• COX20: Late assembly factor

Transcriptional Regulation

PET117 expression is regulated by:

• PGC-1α: Master regulator of mitochondrial biogenesis
• NRF1/2: Nuclear respiratory factors
• mTOR: Growth and nutrient signaling
• AMPK: Energy sensing

Comparative Biology

Evolutionary Conservation

PET117 is conserved across eukaryotes:

| Species | Ortholog | Identity |
|---------|----------|----------|
| Human | PET117 | Reference |
| Mouse | Pet117 | 89% |
| Zebrafish | pet117 | 76% |
| Yeast | PET117 | 52% |

Isoform Complexity

The human PET117 gene produces multiple splice variants with tissue-specific expression patterns.

Biomarker Development

Diagnostic Biomarkers

PET117-related biomarkers under investigation:

• Genetic testing: PET117 mutations in patients
• Complex IV activity: In patient cells
• PET117 expression: In blood or CSF

Progression Markers

Monitoring disease progression:

• Serial complex IV activity measurements
• PET117 protein levels
• Mitochondrial function assays

Clinical Perspectives

Patient Stratification

Understanding PET117 status can guide treatment:

• Genetic testing for PET117 variants
• Complex IV activity measurement
• Mitochondrial function assessment

• Personalized therapeutic strategies based on PET117 genotype
• Tailored interventions for different patient subgroups
• Integration with broader mitochondrial disease diagnostics

Future Directions

Key research priorities:

PET117 and the Electron Transport Chain

Integration with the Respiratory Chain

Complex IV (cytochrome c oxidase) represents the terminal oxidase of the mitochondrial electron transport chain. Its proper function requires tight coupling with upstream complexes:

Complex I Interaction:

• NADH-derived electrons enter through complex I
• Complex IV receives electrons ultimately from ubiquinol
• Proper function requires synchronized activity across all complexes

• Cytochrome c shuttles electrons from complex III to complex IV
• Proton gradient generated at complex III contributes to overall Δp
• Electron transfer kinetics depend on complex IV availability

• Each complex must function properly for optimal ATP production
• Complex IV deficiency reduces overall respiratory capacity
• Oxygen consumption becomes impaired

The Oxygen Reduction Reaction

Complex IV catalyzes the four-electron reduction of oxygen to water:

Catalytic Mechanism:

Energy Conservation:

• This reaction pumps four protons per oxygen molecule reduced
• The energy released drives proton translocation
• This creates the electrochemical gradient used for ATP synthesis

Regulation of Complex IV Activity

Complex IV activity is regulated at multiple levels:

Allosteric Regulation:

• ATP/ADP ratios affect activity
• Thyroid hormone influences expression
• Nitric oxide can inhibit function

• Phosphorylation affects activity
• Acetylation modulates function
• Nitrosylation can regulate activity

• PGC-1α drives expression
• Nuclear respiratory factors (NRF1/2) promote transcription
• Thyroid hormone receptor influences expression

PET117 in Neurodegenerative Disease Models

Alzheimer's Disease Models

Studies in AD models have revealed PET117 connections:

• APP/PS1 mice show altered PET117 expression
• Amyloid-beta treatment decreases complex IV activity
• Mitochondrial dysfunction precedes cognitive decline

Parkinson's Disease Models

In PD models:

• MPTP treatment reduces complex IV function
• Alpha-synuclein aggregation affects mitochondrial integrity
• PET117 expression is altered in dopaminergic neurons

Therapeutic Development Pipeline

Preclinical Stage

Current approaches in development:

Small Molecule Screening:

• High-throughput assays for complex IV enhancers
• Identification of PET117 expression modulators
• Testing of mitochondrial function compounds

• AAV serotype selection for brain delivery
• Promoter optimization for neuronal expression
• Safety and toxicity testing in animal models

Clinical Translation

Challenges in moving to clinic:

• Blood-brain barrier penetration
• Appropriate delivery to affected brain regions
• Optimal dosing and treatment timing
• Patient selection criteria

Signaling Pathway Overview

See Also

• [Mitochondrial Complex IV](/mechanisms/cytochrome-c-oxidase)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Oxidative Phosphorylation](/mechanisms/oxidative-phosphorylation)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Leigh Syndrome](/diseases/leigh-syndrome)
• [Oxidative Stress](/mechanisms/oxidative-stress)
• [Mitochondrial Biogenesis](/mechanisms/mitochondrial-biogenesis)

External Links

• [NCBI Gene: PET117](https://www.ncbi.nlm.nih.gov/gene/55028)
• [UniProt: PET117](https://www.uniprot.org/uniprot/Q8N5N7)
• [Ensembl: PET117](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157103)
• [GeneCards: PET117](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PET117)
• [OMIM: 614970](https://www.omim.org/entry/614970)
• [MitoCarta](https://www.broadinstitute.org/mitocarta) - Mitochondrial protein compendium

References